Which patients receiving warfarin can be treated safely with a drug-eluting stent?

Conversely, stopping warfarin for up to a year and relying on dual antiplatelet therapy may not be sufficient to prevent the risk of disabling or fatal stroke. [...]the dilemma when managing these patients is a fine balance between the risks of in-stent restenosis, stent thrombosis, thromboembolism and bleeding complications. Since the CHADS2 and BRI scores share some common variables it follows that patients with AF at high risk of stroke are also likely to be at higher risk of bleeding.